Extending these data to clinical practice suggests that modulating the TME by targeting the IL-33/CXCR4 signaling circuit may attenuate the aggressiveness of cancer cells and provide a novel therapeutic strategy in precision medicine to improve the prognosis in HNSCC patients. Here, IL33 is linked to cancer.